Michael R. Zile focuses on Internal medicine, Cardiology, Heart failure, Ejection fraction and Heart failure with preserved ejection fraction. His Internal medicine research incorporates themes from Endocrinology and Surgery. His Cardiology research incorporates elements of Angiotensin receptor and Intensive care medicine.
His Heart failure research is multidisciplinary, incorporating perspectives in Valsartan, Enalapril and Diastole. He interconnects Irbesartan, Clinical endpoint, Randomized controlled trial, Cause of death and Hazard ratio in the investigation of issues within Ejection fraction. He has included themes like Spironolactone, Pulmonary hypertension and Atrial fibrillation in his Heart failure with preserved ejection fraction study.
The scientist’s investigation covers issues in Internal medicine, Cardiology, Heart failure, Ejection fraction and Heart failure with preserved ejection fraction. In most of his Internal medicine studies, his work intersects topics such as Endocrinology. As a part of the same scientific study, he usually deals with the Endocrinology, concentrating on Matrix metalloproteinase and frequently concerns with Extracellular matrix.
His work deals with themes such as Irbesartan and Blood pressure, which intersect with Cardiology. Michael R. Zile works mostly in the field of Heart failure, limiting it down to topics relating to Randomized controlled trial and, in certain cases, Baroreflex. His studies in Ejection fraction integrate themes in fields like Diabetes mellitus, Natriuretic peptide, Surgery and Atrial fibrillation.
Internal medicine, Heart failure, Cardiology, Ejection fraction and Heart failure with preserved ejection fraction are his primary areas of study. His research combines Diabetes mellitus and Internal medicine. His work in Heart failure covers topics such as Atrial fibrillation which are related to areas like Left ventricular hypertrophy.
His study in the field of Paradigm hf, Cardiac resynchronization therapy and Sudden death is also linked to topics like In patient. His Ejection fraction study which covers Heart rate that intersects with Renal function, Digoxin and Dialysis. His Heart failure with preserved ejection fraction study integrates concerns from other disciplines, such as Irbesartan, Clinical trial, Coronary artery disease, Exercise intolerance and Myocardial infarction.
His primary areas of study are Heart failure, Internal medicine, Ejection fraction, Cardiology and Heart failure with preserved ejection fraction. Michael R. Zile has researched Heart failure in several fields, including Valsartan and Randomized controlled trial. Michael R. Zile usually deals with Internal medicine and limits it to topics linked to Diabetes mellitus and Aliskiren and MEDLINE.
His Ejection fraction study combines topics in areas such as Blood pressure, Randomization, Hazard ratio, Socioeconomic status and Sudden cardiac death. His work on Pulmonary hypertension as part of general Cardiology research is frequently linked to Value, thereby connecting diverse disciplines of science. His studies deal with areas such as Sudden death, Coronary artery disease, Quality of life, Prediabetes and New York Heart Association Functional Classification as well as Heart failure with preserved ejection fraction.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
John J. V. McMurray;Milton Packer;Akshay S. Desai;Jianjian Gong.
The New England Journal of Medicine (2014)
Diastolic Heart Failure — Abnormalities in Active Relaxation and Passive Stiffness of the Left Ventricle
Michael R. Zile;Catalin F. Baicu;William H. Gaasch.
The New England Journal of Medicine (2004)
Irbesartan in patients with heart failure and preserved ejection fraction
Barry M. Massie;Peter E. Carson;John J. McMurray;Michel Komajda.
The New England Journal of Medicine (2008)
New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part I Diagnosis, Prognosis, and Measurements of Diastolic Function
Michael R. Zile;Dirk L. Brutsaert.
New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment.
Michael R. Zile;Dirk L. Brutsaert.
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial
Scott D. Solomon;Michael R. Zile;Burkert Pieske;Adriaan A Voors.
The Lancet (2012)
Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure The Ancillary Digitalis Investigation Group Trial
Ali Ahmed;Michael W. Rich;Jerome L. Fleg;Michael R. Zile.
Heart failure with a normal ejection fraction: Is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure?
Michael R. Zile;William H. Gaasch;John D. Carroll;Marc D. Feldman.
Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction
Elisabeth Kraigher-Krainer;Amil M. Shah;Deepak K. Gupta;Angela Santos.
Journal of the American College of Cardiology (2014)
Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures.
Michael R. Zile;Tom D. Bennett;Martin St. John Sutton;Yong K. Cho.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: